Le Lézard
Classified in: Health
Subjects: PSF, CFG

STATEMENT - Update on monkeypox in Canada


The Public Health Agency of Canada (PHAC) is issuing this statement to provide an update to the evolving epidemiological investigation into monkeypox cases in Canada.

OTTAWA, ON, May 26, 2022 /CNW/ - Today, the Public Health Agency of Canada (PHAC) is confirming additional cases of monkeypox in Canada. In addition to the previously reported sixteen confirmed cases in Quebec, PHAC's National Microbiology Laboratory (NML) has confirmed another 10 cases. There are now 26 confirmed cases in Canada. The breakdown by province is: Quebec (25) and Ontario (1). It is likely that additional cases will be reported in the coming days as the NML is continuing to receive samples for confirmatory testing from multiple jurisdictions.

Human cases of monkeypox have been recently reported in over 20 countries worldwide. Before now, Canada has not seen person-to-person spread of monkeypox. We are continuing to collaborate with international partners to better understand the arrival of this virus in countries outside of Africa. PHAC, together with health authorities at all levels are actively addressing the situation in Canada to provide the people in Canada with the information they need to make informed decisions about their health. 

The NML is working to facilitate and support laboratory testing capacity in jurisdictions across the country. The Agency is engaging with experts to finalize and release public health guidance on case identification, contact tracing and isolation, as well as infection and prevention control for the healthcare system. The NML is also completing whole genome sequencing, an enhanced fingerprint analysis, on Canadian samples of monkeypox. This sequencing will help our experts understand the chains of transmission occurring in Canada.

Additionally, there is ongoing work to plan the way forward with provinces, territories and partners, such as providing access to approved vaccines in Canada that, if required, can be used in managing monkeypox in their jurisdiction. As a preparedness step, limited shipments of Imvamune vaccine from Canada's National Emergency Strategic Stockpile (NESS) are being offered to jurisdictions who require a targeted response. Currently, there is no need for the vaccine to be used for mass immunization. This recommendation is in alignment with international expert assessments, including the World Health Organization (WHO). The situation in Canada is under close and constant monitoring and may be adapted as and when the need arises.

While the risk of infection is currently low for the general population, monkeypox virus can affect anyone who is in close contact with an infected person or their contaminated objects. Contrary to some recent media reports, this virus does not discriminate and is not limited to spread from intimate sexual activities. This kind of misinformation and stigmatization can lead to misunderstanding of risks and negative health outcomes. Canada's Chief Medical Officers of Health are meeting regularly and working collaboratively to analyze available information about these emerging human infections that before now, have never before been reported in Canada.

Canadians should be aware of the symptoms of monkeypox. Anyone who may have come into contact with a case or who is feeling unwell or has symptoms that could be consistent with monkeypox infection, should limit their contact with others and report their symptoms to their health care provider. Common signs and symptoms of monkeypox infection include fever, headache, muscle aches, exhaustion, swollen lymph nodes, and development of a new rash. Following infection, the incubation period (number of days between exposure/infection and onset of symptoms) is normally 6-13 days but can range to as much as 21 days. Health care providers are urged to be extra vigilant and closely watch for patients with any symptoms of monkeypox, even atypical presentation, regardless of whether they have reported travel.

The Government of Canada will continue to work with the provinces and territories to respond to the evolving situation, and will continue to provide updates to the public as new information becomes available.

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 08:05
NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international...

at 08:05
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that new data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3...

at 08:05
PsychoGenics Inc. ("PsychoGenics" or the "Company"), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has appointed David Bleakman, Ph.D., to President, Drug Discovery and Development, and Thomas...

at 08:04
The American Liver Foundation (ALF) will bring together leading rare liver disease experts and clinicians, patients, caregivers, advocacy organizations and industry representatives for a virtual two-day Summit, June 28-29, to identify solutions which...

at 08:03
Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease's most significant challenges through the creative applications of nanotechnology, today announced the closing of its oversubscribed $7.2...

at 08:03
Trinity Health Of New England and Nest Collaborative announced the launch of a new program providing telehealth breastfeeding support to families giving birth at the integrated health system's hospitals in Connecticut and Massachusetts....



News published on 26 may 2022 at 18:36 and distributed by: